Cargando…

Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs

Chronic lymphocytic leukemia (CLL) is an adult lymphoid malignancy with a variable clinical course. There is considerable interest in the identification of new treatments, as most current approaches are not curative. While most patients respond to initial chemotherapy, relapsed disease is often resi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Min, Zhang, Yaqin, Saba, Nakhle, Austin, Christopher P., Wiestner, Adrian, Auld, Douglas S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779154/ https://www.ncbi.nlm.nih.gov/pubmed/24073257 http://dx.doi.org/10.1371/journal.pone.0075252

Ejemplares similares

Correction: Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs
por: Shen, Min, et al.
Publicado: (2013)

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia
por: Karsa, Mawar, et al.
Publicado: (2022)

The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia
por: Sun, Clare, et al.
Publicado: (2022)

Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
por: Shapiro, Mika, et al.
Publicado: (2017)

Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia
por: Hoeksema, Kimberley A, et al.
Publicado: (2011)

Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library
por: Wang, Peilin, et al.
Publicado: (2018)

Screening and Identification of Lujo Virus Entry Inhibitors From an Food and Drug Administration-Approved Drugs Library
por: Cao, Junyuan, et al.
Publicado: (2021)

Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library
por: Feng, Jie, et al.
Publicado: (2014)

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
por: Herman, Sarah E. M., et al.
Publicado: (2014)

Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library
por: Pascoalino, Bruno S., et al.
Publicado: (2016)

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
por: Jeon, Sangeun, et al.
Publicado: (2020)

Targeting the Fcμ-receptor in chronic lymphocytic leukemia with a novel IgM-derived antibody-drug conjugate
por: Skarzynski, Martin, et al.
Publicado: (2013)

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021)

Recent drug approvals for acute myeloid leukemia
por: Lai, Catherine, et al.
Publicado: (2019)

FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal
por: Mei, Yikun, et al.
Publicado: (2020)

Integration of genetically regulated gene expression and pharmacological library provides therapeutic drug candidates
por: Konuma, Takahiro, et al.
Publicado: (2021)

Identification of drug candidates that enhance pyrazinamide activity from a clinical compound library
por: Niu, Hongxia, et al.
Publicado: (2017)

Successful treatment of “accelerated” chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.
por: Xie, John, et al.
Publicado: (2021)

Screening of Natural Products and Approved Oncology Drug Libraries for Activity against Clostridioides difficile
por: Pal, Rusha, et al.
Publicado: (2020)

Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia
por: Sachdeva, Mamta, et al.
Publicado: (2015)

Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
por: Cyr, Matthew G, et al.
Publicado: (2022)

Composition and applications of focus libraries to phenotypic assays
por: Wassermann, Anne Mai, et al.
Publicado: (2014)

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma
por: Lakhotia, Rahul, et al.
Publicado: (2022)

Identification of Modulators of HIV-1 Proviral Transcription from a Library of FDA-Approved Pharmaceuticals
por: Sampey, Gavin C., et al.
Publicado: (2020)

Siglec-6 is a Target for Chimeric Antigen Receptor T-cell Treatment of Chronic Lymphocytic Leukemia
por: Kovalovsky, Damian, et al.
Publicado: (2021)

Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics
por: Cooper, Callum J., et al.
Publicado: (2016)

Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development
por: Stanchina, Michele, et al.
Publicado: (2020)

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
por: Lammers, Austin, et al.
Publicado: (2017)

Identification of NUDT5 Inhibitors From Approved Drugs
por: Tong, Xin-Yu, et al.
Publicado: (2020)

In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria
por: Peyclit, Lucie, et al.
Publicado: (2022)

Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation
por: Voss, Linda, et al.
Publicado: (2021)

Comprehensive Characterization of Cytochrome P450 Isozyme Selectivity across Chemical Libraries
por: Veith, Henrike, et al.
Publicado: (2009)

Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection
por: Veljkovic, Veljko, et al.
Publicado: (2015)

Approval success rates of drug candidates based on target, action, modality, application, and their combinations
por: Yamaguchi, Shingo, et al.
Publicado: (2021)

Therapeutic advancement of chronic lymphocytic leukemia
por: Lu, Kang, et al.
Publicado: (2012)

Therapeutic Targets in Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2020)

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
por: Shityakov, Sergey, et al.
Publicado: (2021)

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia
por: Herman, SEM, et al.
Publicado: (2013)

New drug approvals in acute myeloid leukemia: what’s the best end point?
por: Estey, E, et al.
Publicado: (2015)

Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma
por: Chahal, Kirti Kandhwal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f5s8817df8jl6n68r69s35bq6n